Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eldec-Sel
Durham, North Carolina, United Stateseldecsel.in ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Eldec Pharmaceuticals develops novel peptide therapeutics targeting the Orai1 calcium channel for chronic lung diseases. Their lead candidate, ELD607, derived from a sequence in the C-terminal region of SPLUNC1, has demonstrated significant reversal of existing lung damage and reduction in neutrophilia and bacterial load—including methicillin-resistant S. aureus—in preclinical animal models. The approach offers a new immunomodulatory strategy for treating both inflammation-driven pulmonary disease and antibiotic-resistant infections.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- PeptidesSmall molecule (for some programs, but primary focus is peptide therapeutics)
- Industry
- Biotech
02
Partnerships
Funding support from NHLBI, NIAID, North Carolina Biotechnology Center; no major pharma partnerships disclosed as of June 2025.
Beyond the preview
Go deeper on Eldec-Sel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eldec-Sel.